Global chronic obstructive pulmonary disease device market could hit $34 billion by 2020

2 December 2014

The global chronic obstructive pulmonary disease and asthma devices market is expected to reach $34 billion by 2020, according to a new report by Allied Market Research.

Its Global COPD and Asthma Devices Market – Size, Industry, Analysis, Trends, Opportunities, Growth and Forecsat, 2013-2020 report predicts compound annual growth of 4.5% between 2014 and 2020, bringing the total market value to $34.3 billion. Dry powder inhalers will be the most lucrative segment of the market, overtaking metered dose inhalers. The dry powder inhaler segment is predicted to grow at a compound annual growth rate of 5.3%.

Urgency in medication and improved drug delivery devices will drive the growth in this market. The fact that metered dose inhalers release environmentally-hazardous gases such as chlorofluorocarbon and hydrofluoroalkanes could negatively impact growth of that segment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK